Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

Conference Call Scheduled for September 17 at 10:30 ET, 7:30 PT

EMERYVILLE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced its financial results for its fiscal fourth quarter and year ended June 30, 2007 and announced a planned 1-for-7 reverse split of its common stock.

For fiscal year 2007, the Company reported revenue of $17.7 million, a 44% increase over last year's revenue of $12.3 million. The net loss for fiscal 2007 was $14.1 million, or $0.47 per share, compared with a net loss of $27.8 million, or $0.98 per share, in fiscal year 2006. At June 30, 2007, the Company's balance of available cash, cash equivalents and investment securities was $8.9 million.

For the fourth quarter ended June 30, 2007, the Company reported revenue of $4.0 million compared to $4.3 million for the same period in 2006. The net loss for the quarter ended June 30, 2007 was $4.2 million, or $0.13 per share, compared with a net loss of $4.8 million, or $0.16 per share, for the same period in 2006.

For the fiscal year ended June 30, 2007, the Company reported revenue of $17.7 million consisting of $6.9 million of royalty fees earned from the commercial sales of memantine by Merz + Co. GmbH & Co. (Merz) and its marketing partners in the United States and certain European countries, $5.5 million from the sale of NTI's rights and assets related to XERECEPT(R) to Celtic Pharmaceutical Holdings L.P. (Celtic), and $5.3 million from the reimbursement of the direct expenses incurred for services provided to Celtic for administering the Phase III clinical trials for XERECEPT in the United States. The Company's fiscal year 2006 revenues of $12.3 million
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SoundConnect , an award winning ... to announce the addition of Adobe Connects Learning ... tools to quickly deploy and manage online courses ... for desktop and mobile learning solutions. , Adobe ... online training solution, enabling organizations to deploy, measure, ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... SAN and NYSE: SNY) today announced that the Companies ... (FDA) rare pediatric disease priority review voucher in connection ...  The priority review voucher entitles the holder to designate ... expedited 6-month review from the filing date instead of ...
(Date:7/30/2014)... 2014  Replikins Ltd. today released new data on ... Before the current outbreaks, the mean Ebola Reston gene ... between 1995 and 2002 was 1.1; the mean Replikin ... sixteen-fold in 2013, thus predicting the current outbreaks in ... been shown to be able to predict outbreaks (1). ...
(Date:7/30/2014)... 30, 2014 With the accelerated ... personal health expenditure as well as the improved ... China diagnostic reagent industry has been developing quickly, ... In 2013, Chinese in vitro diagnostics market size ... from in vitro diagnostic reagents. , Read ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3
... , New kinase array designed for ... VANCOUVER , Feb. 10 /PRNewswire/ - ... novel Protein Kinase Microarray with 200 recombinant human protein ... applications for drug target counter screening, to identify novel ...
... AeroLEF patents granted in Europe , China ... Feb. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... patents in the US for AeroLEF(R), the Company,s proprietary, inhaled-delivery ... treatment of moderate to severe acute pain. US patent numbers ...
... ... Liquid Separation Training on March 22nd in San Antonio, Texas, USA. AFS is holding its ... Texas. There will be eleven courses held on March 22nd. Six of these courses are ... , ...
Cached Biology Technology:Kinexus Announces the Launch of a New Protein Kinase Microarray 2YM BioSciences granted two US patents for AeroLEF(R) 2YM BioSciences granted two US patents for AeroLEF(R) 3YM BioSciences granted two US patents for AeroLEF(R) 4Water Filtration and Liquid Separation Training by the American Filtration and Separations Society. 2Water Filtration and Liquid Separation Training by the American Filtration and Separations Society. 3Water Filtration and Liquid Separation Training by the American Filtration and Separations Society. 4Water Filtration and Liquid Separation Training by the American Filtration and Separations Society. 5
(Date:7/30/2014)... group of researchers from the University of Helsinki and ... to reproduce in mice morphological changes which have taken ... modifications in the embryonic development of mice teeth, induced ... are very similar to those observed in the fossil ... of years ago. , To modify the development ...
(Date:7/30/2014)... team of biologists, led by Clemson University associate professor ... pest that will pave the way for novel anti-fouling ... for medical and industrial applications. , The team,s findings, ... the last larval stage of barnacles that attaches to ... possibly polymeric material that acts as an underwater heavy-duty ...
(Date:7/30/2014)... Limited today announced an across-the-board increase in Impact ... 2013 InCites Journal Citation Reports (Thomson Reuters, 2014) ... Journal , Essays in Biochemistry , ... all received increases in their Impact Factors. ... and published by Portland Press Limited. , 2014 ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2
... active a living cell is can be seen by its ... been significantly improved by chemists in Bochum. The problem up ... consumption in the cell,s environment much more than the cell ... Prof. Dr. Wolfgang Schuhmann from the Department of Analytical Chemistry ...
... green sea turtles are benefiting from marine protected areas by ... Geological Survey study that is the first to track the ... turtles are listed as endangered in Florida and threatened throughout ... sea turtles after their forays to nest on beaches in ...
... the earthworm, is great at protecting leaves from being chomped ... BMC Ecology . Although they lurk in the soil, ... diversity also decreases the amount of damage slugs do to ... among the top 100 worst alien species in Europe and ...
Cached Biology News:How much a single cell breathes 2Sea turtles benefiting from protected areas 2Sea turtles benefiting from protected areas 3
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
... The pPIC9K and pPIC3.5K vectors carry ... to Geneticin Reagent in Pichia. Spontaneous generation ... by resistance to increased levels of Geneticin ... medium and screened for their level of ...
...
... Kit provides an extremely fast and ... intact protein complexes. Unlike other systems ... purification steps, this system takes advantage ... Column for fast protein purification under ...
Biology Products: